Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Langsigtede resultater af endoskopisk assisteret vs konventionel brystbevarende kirurgi hos brystkræftpatienter efter neoadjuverende terapi: et randomiseret, multicenter, åbent, non-inferioritetsforsøg

With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

804

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Guangdong
      • Guangzhou, Guangdong, Kina, 510120
        • Rekruttering
        • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
        • Kontakt:
      • Shantou, Guangdong, Kina
        • Ikke rekrutterer endnu
        • Sun Yat-sen Memorial Hospital of Sun Yat-sen University Shenzhen Shantou Central Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Age ranging from 18 to 75 years
  2. Pathologically confirmed invasive breast cancer
  3. Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen)
  4. cT1-3N0-3M0
  5. Unilateral breast tumor
  6. Eastern Cooperative Oncology Group score 0-1
  7. Left Ventricular Ejection Fraction (LVEF) ≥50%
  8. Leukocytes ≥ 3.0×109/L, Absolute neutrophil count ≥ 1.5×109/L, Platelets ≥ 100×109/L, Hemoglobin ≥ 90g/L, Creatinine <1.5 × institutional ULN, Total bilirubin ≤ 2.0 × institutional ULN.

Exclusion Criteria:

  1. Diffusely disseminated malignant calcification foci
  2. Not applicable for BCS after neoadjuvant therapy
  3. Pregnancy or breastfeeding
  4. Additional malignancy
  5. Severe cardiopulmonary, liver or kidney dysfunction or other systemic diseases (such as uncontrolled chronic heart failure, critical hypertension or diabetes with poor blood glucose control).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Endoskopisk brystbevarende kirurgi (E-BCS) gruppe

comparison of 2 surgical procedures

Ingen indgriben: Konventionel brystbevarende kirurgi (C-BCS) gruppe

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
5-year disease free survival
Tidsramme: From surgery to the end of follow-up at 5 years

The proportion of patients remaining after excluding patients with disease recurrence, metastasis or death from the time of surgery to 5-year follow-up

From surgery to the end of follow-up at 5 years
Patients' satisfaction with breast
Tidsramme: From surgery to the follow-up at 6 months

The score of Breast-Q scale "Satisfaction with breasts" table 6 months after surgery

From surgery to the follow-up at 6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Surgeons' satisfaction with breast
Tidsramme: From surgery to the follow-up at 6 months

Surgeons evaluate the cosmetic outcome of breast based on the photos before surgery and after surgery. Four ranks: Excellent (9-10 points), Good (7-8 points), Fair (5-6 points) and Poor (0-4 points) are categorized on a basis of average total score from Ueda scale

From surgery to the follow-up at 6 months
Patients satisfaction with scar
Tidsramme: From surgery to the follow-up at 6 months

Scar-Q scale including 3 tables about the surgical scar: appearance, symptom, psychosocial impact with total score of 100 will be used for evaluating patients satisfaction with scar

From surgery to the follow-up at 6 months
5-year overall survival
Tidsramme: From surgery to the end of follow-up at 5 years

The proportion of patients remaining after excluding patients who died from any cause at 5-year follow-up

From surgery to the end of follow-up at 5 years
5-year local-regional recurrence rate
Tidsramme: From surgery to the end of follow-up at 5 years

The proportion of patients with a lump found on breast, axilla, chest wall, skin or scars of surgery ipsilateral to the surgical side through physical examination or imaging, confirmed as the same pathological type as the primary tumor according to biopsy at 5-year follow up

From surgery to the end of follow-up at 5 years
Postoperative complication rate
Tidsramme: From surgery to the follow-up at 12 months

The proportion of patients with postoperative complications including hemorrhage, incision dehiscence, upper limb lymphedema, infection,seroma.

From surgery to the follow-up at 12 months
Surgical duration
Tidsramme: Intraoperative

The time from the beginning of surgery to the end of surgery

Intraoperative
Intraoperative blood loss
Tidsramme: Intraoperative

The blood loss during the operation

Intraoperative
Incision length
Tidsramme: Intraoperative

The length of surgical incision

Intraoperative

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studiestol: Shicheng Su, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. august 2024

Primær færdiggørelse (Anslået)

1. januar 2033

Studieafslutning (Anslået)

1. januar 2033

Datoer for studieregistrering

Først indsendt

29. november 2024

Først indsendt, der opfyldte QC-kriterier

3. december 2024

Først opslået (Faktiske)

4. december 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. september 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • SYSKY-2024-648-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner